hp 873 has been researched along with Schizophrenia in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (28.85) | 29.6817 |
| 2010's | 32 (61.54) | 24.3611 |
| 2020's | 5 (9.62) | 2.80 |
| Authors | Studies |
|---|---|
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Narala, A; Suram, D; Veerabrahma, K | 1 |
| Asamoah, AL; Gosal, R; Grossberg, GT; Nair, A; Salem, A | 1 |
| Hewitt, T; Khokhar, JY; Lalonde, J; Perreault, ML; St-Denis, M; Thériault, RK | 1 |
| Danek, PJ; Daniel, WA; Kuban, W | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Dargani, NV; Malhotra, AK | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Geerts, H; Potkin, S; Roberts, P; Spiros, A | 1 |
| Mandrioli, R; Mercolini, L; Protti, M | 1 |
| Ahmed, S; Han, G; Mancione, L; Manning, R; Mayo, MG; Ryan, JM; Weiden, PJ; Wolfgang, CD | 1 |
| Hamilton, J; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Thompson, A; Volpi, S; Wolfgang, CD | 1 |
| Hamilton, JB; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Lavedan, C; Licamele, L; Malhotra, AK; Potkin, SG; Volpi, S | 1 |
| Citrome, L | 5 |
| Scott, LJ | 1 |
| Cutler, AJ | 1 |
| Lavedan, C; Thompson, A; Volpi, S | 1 |
| Caccia, S; Nobili, A; Pasina, L | 1 |
| Caballero, J; Marino, J | 1 |
| Janicak, PG; Rado, J | 1 |
| Bishop, DL; Bishop, JR | 1 |
| Roman, MW | 1 |
| Dopheide, JA | 1 |
| Arif, SA; Mitchell, MM | 1 |
| Howland, RH | 1 |
| Crabtree, BL; Montgomery, J | 1 |
| Citrome, L; Hochfeld, M; Meng, X | 1 |
| Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Weiden, PJ | 1 |
| Hopkins, CR | 1 |
| Stahl, SM; Tarazi, FI | 1 |
| Correll, CU; De Hert, M; Detraux, J; Sweers, K; van Winkel, R; Yu, W | 1 |
| Bobo, WV | 1 |
| Cutler, AJ; Kalali, AH; Kunovac, J; Mattingly, GW; Meng, X | 1 |
| Freeman, SA | 1 |
| Albers, LJ; Musenga, A; Raggi, MA | 1 |
| Lavedan, C; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Potkin, SG | 1 |
| Cutler, AJ; Polymeropoulos, MH; Weiden, PJ; Wolfgang, CD | 1 |
| Cutler, AJ; Hamilton, J; Kalali, AH; Weiden, PJ; Wolfgang, CD | 1 |
| Di Marino, M; Kane, JM; Laska, E; Lauriello, J; Wolfgang, CD | 1 |
| Litman, RE; Potkin, SG; Torres, R; Wolfgang, CD | 1 |
| Jain, KK | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
27 review(s) available for hp 873 and Schizophrenia
| Article | Year |
|---|---|
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
An update on the efficacy and safety of iloperidone as a schizophrenia therapy.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Weight Gain | 2020 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
Safety profile of iloperidone in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2014 |
Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Drug Design; Drug Monitoring; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Drug Labeling; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Sample Size; Schizophrenia; Treatment Outcome | 2009 |
Iloperidone: in schizophrenia.
Topics: Humans; Internationality; Isoxazoles; Multicenter Studies as Topic; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2009 |
Iloperidone: a new option for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Confidence Intervals; Humans; Isoxazoles; Kaplan-Meier Estimate; Longitudinal Studies; Piperidines; Schizophrenia | 2009 |
New atypical antipsychotics for schizophrenia: iloperidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2010 |
Iloperidone for schizophrenia.
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Drug Approval; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Drug Interactions; Evidence-Based Medicine; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Precision Medicine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Topics: Adult; Animals; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Half-Life; Humans; Isoxazoles; Piperidines; Receptors, Adrenergic, alpha-1; Schizophrenia | 2010 |
Iloperidone: A new drug for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Humans; Isoxazoles; Piperidines; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2011 |
Iloperidone for the management of adults with schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2011 |
Iloperidone: a clinical overview.
Topics: Antipsychotic Agents; Electrocardiography; Heart Rate; Humans; Isoxazoles; Long QT Syndrome; Piperidines; Schizophrenia; Treatment Outcome; Weight Gain | 2011 |
Iloperidone for the treatment of schizophrenia: an updated clinical review.
Topics: Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Hospitalization; Humans; Isoxazoles; Piperidines; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2012 |
ACS chemical neuroscience molecule spotlight on Fanapt.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Device Approval; Dopamine Agonists; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; United States; United States Food and Drug Administration | 2010 |
Iloperidone, asenapine and lurasidone: a primer on their current status.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lipid Metabolism; Lurasidone Hydrochloride; Paliperidone Palmitate; Piperidines; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2013 |
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Isoxazoles; Marketing; Piperidines; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Structure-Activity Relationship | 2008 |
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Patient Dropouts; Piperidines; Prospective Studies; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2008 |
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Prospective Studies; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
An assessment of iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2000 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
13 trial(s) available for hp 873 and Schizophrenia
| Article | Year |
|---|---|
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Recurrence; Schizophrenia; Secondary Prevention; Treatment Outcome | 2016 |
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Genome-Wide Association Study; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Isoxazoles; Male; Middle Aged; Nerve Tissue Proteins; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Pseudogenes; Receptors, AMPA; Schizophrenia; Tenascin; Thiazoles; Transcription Factors; Young Adult | 2009 |
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Carrier Proteins; CELF Proteins; Cytoskeletal Proteins; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Isoxazoles; Linear Models; Linkage Disequilibrium; Long QT Syndrome; Male; Middle Aged; Neuregulins; Organic Anion Transporters; Pharmacogenetics; Phosphoproteins; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Piperidines; Polymorphism, Single Nucleotide; RNA-Binding Proteins; Schizophrenia; Thiazoles; Young Adult | 2009 |
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Double-Blind Method; Female; Genetic Markers; Genotype; Humans; Isoxazoles; Likelihood Functions; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Probability; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
Topics: Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Gene Frequency; Genotype; Humans; Isoxazoles; Male; Piperazines; Piperidines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2C; Schizophrenia; Thiazoles; Weight Gain | 2010 |
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Mood Disorders; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult | 2011 |
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Topics: Adult; Antipsychotic Agents; Apoptosis Regulatory Proteins; Benzodiazepines; Biomarkers, Pharmacological; Black or African American; Drug Resistance; Genotype; Humans; Isoxazoles; Membrane Proteins; Membrane Transport Proteins; Olanzapine; Piperidines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, AMPA; Risperidone; Schizophrenia; White People | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Humans; India; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; United States; Young Adult | 2013 |
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
Topics: Adult; Antipsychotic Agents; Ciliary Neurotrophic Factor; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Placebos; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Racial Groups; Schizophrenia; Schizophrenic Psychology | 2008 |
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Thiazoles; Treatment Outcome | 2008 |
12 other study(ies) available for hp 873 and Schizophrenia
| Article | Year |
|---|---|
Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Chemistry, Pharmaceutical; Dizocilpine Maleate; Drug Carriers; Emulsions; Excipients; Humans; Isoxazoles; Locomotion; Male; Models, Animal; Particle Size; Piperidines; Rats; Schizophrenia; Solubility; Surface-Active Agents; Suspensions; Tablets | 2020 |
Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Cannabidiol; Cell Culture Techniques; Cerebral Cortex; Disease Models, Animal; Female; Isoxazoles; Male; Neurons; Piperidines; Rats; Rats, Sprague-Dawley; Schizophrenia; Sex Characteristics | 2021 |
The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms.
Topics: Animals; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Gene Expression; Isoxazoles; Liver; Male; Microsomes, Liver; Piperidines; Rats; Rats, Wistar; Schizophrenia | 2021 |
Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.
Topics: Antipsychotic Agents; Computer Simulation; Genotype; Humans; Isoxazoles; Models, Biological; Molecular Targeted Therapy; Neurobiology; Pharmacogenetics; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2015 |
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Iloperidone (Fanapt)--another second-generation antipsychotic.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Atypical antipsychotics: the two new arrivals.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Piperidines; Safety; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Iloperidone: Does it have a meaningful place in therapy?
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Humans; Isoxazoles; Piperidines; Schizophrenia | 2011 |
Update on newer antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Pregnancy; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Iloperidone-induced retrograde ejaculation.
Topics: Antipsychotic Agents; Capgras Syndrome; Ejaculation; Humans; Isoxazoles; Male; Piperidines; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult | 2013 |
New advances in the treatment of schizophrenia. Introduction.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2008 |
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Endpoint Determination; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |